Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 21;27(150):180077.
doi: 10.1183/16000617.0077-2018. Print 2018 Dec 31.

The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype

Affiliations
Review

The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype

Amy L Olson et al. Eur Respir Rev. .

Abstract

The availability of epidemiological data relating to interstitial lung diseases (ILDs) has increased over recent years, but information on the prevalence and incidence of ILDs of different aetiologies remains limited. Despite global distribution, the proportion of patients who develop a progressive phenotype across different ILDs is not well known. Disease behaviour is well documented in idiopathic pulmonary fibrosis but idiosyncratic in other ILDs that may present a progressive fibrosing phenotype. Possible reasons may include the heterogeneous nature of the aetiology, the complexity of diagnosis (and subsequent documentation of cases) and the methods employed to retrospectively analyse patient databases. This review presents a broad overview of the epidemiological data available for ILDs that may present a progressive-fibrosing phenotype, collectively and stratified according to clinical classification. We also note where further data are needed in comparison to the well-studied IPF indication.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: A.L. Olson reports receiving the following, outside the submitted work: support from United Therapeutics for study enrolment IPF; support from Boehringer Ingelheim for unbranded IPF talks; support from France Foundation and the PILOT Program for project development for IPF/speaker/content development on talks for IPF; a grant from Bellerophon Pulse Technologies; and support from Boehringer Ingelheim Speaker's Bureau, Boehringer Ingelheim Consultancy, Genentech Advisory Board, Genentech Consultancy Services and Vindico CME Educational Development. Conflict of interest: A.H. Gifford reports receiving nonfinancial support from Ashfield Healthcare Communications (part of UDG Healthcare pc) for assistance with preparation of the current work. A.H. Gifford also received personal fees from Grifols, outside the submitted work. Conflict of interest: N. Inase has nothing to disclose. Conflict of interest: E.R. Fernández Pérez reports receiving personal fees from BI, outside the submitted work. Conflict of interest: T. Suda has nothing to disclose.

Comment in

  • doi: 10.1183/16000617.0110-2018

References

    1. Raghu G. Interstitial lung disease. In: Goldman L, Schafer A. Goldman's Cecil Medicine. 25th Edn. Philadelphia, Saunders, 2016; pp. 575–588.
    1. Flaherty KR, Brown KK, Wells AU, et al. . Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. BMJ Open Respir Res 2017; 4: e000212. - PMC - PubMed
    1. Wells AU, Brown KK, Flaherty KR, et al. . What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51: 1800692. - PubMed
    1. Raghu G, Collard HR, Egan JJ, et al. . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824. - PMC - PubMed
    1. Cottin V, Hirani NA, Hotchkin DL, et al. . Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 2018; 27: 180076. - PMC - PubMed

MeSH terms